Cargando…
CRISPR-mediated MECOM depletion retards tumor growth by reducing cancer stem cell properties in lung squamous cell carcinoma
Targeted therapy for lung squamous cell carcinoma (LUSC) remains a challenge due to the lack of robust targets. Here, we identified MECOM as a candidate of therapeutic target for LUSC by screening 38 genes that were commonly amplified in three pairs of primary tumors and patient-derived xenografts (...
Autores principales: | Ma, Yuanyuan, Kang, Bin, Li, Shaolei, Xie, Guoyun, Bi, Jiwang, Li, Fuqiang, An, Guo, Liu, Bing, Li, Jing, Shen, Yue, Xu, Xun, Yang, Huanming, Yang, Yue, Gu, Ying, Wu, Nan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637721/ https://www.ncbi.nlm.nih.gov/pubmed/35733338 http://dx.doi.org/10.1016/j.ymthe.2022.06.011 |
Ejemplares similares
-
MECOM promotes supporting cell proliferation and differentiation in cochlea
por: Chen, Peipei, et al.
Publicado: (2022) -
Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme
por: Hou, Aiwu, et al.
Publicado: (2016) -
Epigenetic landscape reveals MECOM as an endothelial lineage regulator
por: Lv, Jie, et al.
Publicado: (2023) -
Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification
por: Cornet, Edouard, et al.
Publicado: (2016) -
Phenotypic heterogeneity in individuals with MECOM variants in 2 families
por: Niihori, Tetsuya, et al.
Publicado: (2022)